Centessa announces Part 5 data from ongoing Phase 2a study of SerpinPC

Centessa Pharmaceuticals announced new data from an additional 52-weeks of continuous treatment from the third year — Part 5 — of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C in registrational studies for the treatment for hemophilia B, with or without inhibitors. Part 5 data from the Phase 2a study showed a continued favorable safety and tolerability profile for SerpinPC, as well as sustained long-term efficacy results, as measured by a 96% reduction in the median all-bleed annualized bleeding rate from the prospective baseline. Consistent with data from earlier portions of the Phase 2a study, there were no thromboembolic events and no treatment-related sustained elevations of D-dimer observed throughout Part 5. D-dimer is a sensitive measure of excess thrombin generation. In addition, there were no SerpinPC-related adverse events observed during Part 5.